Exeltis Usa Inc patents expiration
1. Drospirenone patents expiration
DROSPIRENONE's oppositions filed in EPO
Can you believe DROSPIRENONE received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9603860 | EXELTIS USA INC | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
Jun, 2031
(7 years from now) | |
| US11351122 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(7 years from now) | |
| US10849857 | EXELTIS USA INC | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
Jun, 2031
(7 years from now) | |
| US10603281 | EXELTIS USA INC | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
Jun, 2031
(7 years from now) | |
| US11413249 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(7 years from now) | |
| US11123299 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(7 years from now) | |
| US11439598 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(7 years from now) | |
| US11291633 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(7 years from now) | |
| US10987364 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(7 years from now) | |
| US11478487 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(7 years from now) | |
| US11504334 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(7 years from now) | |
| US11291632 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(7 years from now) | |
| US10179140 | EXELTIS USA INC | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
Jun, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 29, 2025 |
Drugs and Companies using DROSPIRENONE ingredient
Market Authorisation Date: 29 June, 2022
Treatment: Prevention of pregnancy in females of reproductive age
Dosage: TABLET, CHEWABLE;ORAL
More Information on Dosage
DROSPIRENONE family patents
2. Estrasorb patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5629021 | EXELTIS USA INC | Micellar nanoparticles |
Jan, 2015
(9 years ago) | |
Drugs and Companies using ESTRADIOL HEMIHYDRATE ingredient
Market Authorisation Date: 09 October, 2003
Treatment: NA
Dosage: EMULSION;TOPICAL
More Information on Dosage
ESTRASORB family patents
3. Slynd patents expiration
SLYND's oppositions filed in EPO
Can you believe SLYND received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10849857 | EXELTIS USA INC | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
Jun, 2031
(7 years from now) | |
| US11123299 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(7 years from now) | |
| US10179140 | EXELTIS USA INC | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
Jun, 2031
(7 years from now) | |
| US10603281 | EXELTIS USA INC | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
Jun, 2031
(7 years from now) | |
| US11413249 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(7 years from now) | |
| US11504334 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(7 years from now) | |
| US11439598 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(7 years from now) | |
| US11291632 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(7 years from now) | |
| US11291633 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(7 years from now) | |
| US11351122 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(7 years from now) | |
| US9603860 | EXELTIS USA INC | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
Jun, 2031
(7 years from now) | |
| US11478487 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(7 years from now) | |
| US10987364 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 23, 2022 |
Drugs and Companies using DROSPIRENONE ingredient
Market Authorisation Date: 23 May, 2019
Treatment: Prevention of pregnancy in females of reproductive age
Dosage: TABLET;ORAL
How can I launch a generic of SLYND before it's drug patent expiration?
More Information on Dosage
SLYND family patents